EMRELIS
Live / Registered — Registered (as of 11 Aug 2026)
What this means for you
Registered since 11 Aug 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 11 Aug 2032: the §8 declaration of use).
Record
- Serial number
- 97631084
- Registration number
- 8392936
- Mark type
- Word mark
- Filed
- 13 Oct 2022
- Published for opposition
- 14 Mar 2023
- Registered
- 11 Aug 2026
- Next maintenance filing
- §8 declaration of use, due by 11 Aug 2032 (grace period to 11 Feb 2033)
- Attorney of record
- Maryam S. Arastu
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders
Owner
- AbbVie Inc., North Chicago, IL, US
- AbbVie Inc., North Chicago, IL, US
- AbbVie Inc., North Chicago, IL, US
Prosecution history
- 11 Aug 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 11 Aug 2026 — REGISTERED-PRINCIPAL REGISTER
- 20 Jul 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Jul 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 06 Jul 2026 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 06 Jul 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 06 Jul 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 06 Jul 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 06 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 06 Jul 2026 — ASSIGNED TO LIE
- 01 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 15 Apr 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 15 Apr 2026 — NON-FINAL ACTION E-MAILED
- 15 Apr 2026 — SU - NON-FINAL ACTION - WRITTEN